Zhu Y - Search Results

1

Resistance profile and mechanism of severe acute respiratory syndrome coronavirus-2 variants to LCB1 inhibitor targeting the spike receptor-binding motif.

Wu T, Zhu Y, Liu N, Hu Y, Chong H, He Y. Wu T, et al. Among authors: zhu y. Front Microbiol. 2022 Oct 11;13:1022006. doi: 10.3389/fmicb.2022.1022006. eCollection 2022. Front Microbiol. 2022. PMID: 36304946 Free PMC article.

2

A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.

Xiong S, Borrego P, Ding X, Zhu Y, Martins A, Chong H, Taveira N, He Y. Xiong S, et al. Among authors: zhu y. J Virol. 2016 Dec 16;91(1):e01839-16. doi: 10.1128/JVI.01839-16. Print 2017 Jan 1. J Virol. 2016. PMID: 27795437 Free PMC article.

3

A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent In Vitro, Ex Vivo, and In Vivo Antiviral Activity.

Chong H, Xue J, Xiong S, Cong Z, Ding X, Zhu Y, Liu Z, Chen T, Feng Y, He L, Guo Y, Wei Q, Zhou Y, Qin C, He Y. Chong H, et al. Among authors: zhu y. J Virol. 2017 May 12;91(11):e00288-17. doi: 10.1128/JVI.00288-17. Print 2017 Jun 1. J Virol. 2017. PMID: 28356533 Free PMC article.

4

Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.

Ding X, Zhang X, Chong H, Zhu Y, Wei H, Wu X, He J, Wang X, He Y. Ding X, et al. Among authors: zhu y. J Virol. 2017 Aug 24;91(18):e00831-17. doi: 10.1128/JVI.00831-17. Print 2017 Sep 15. J Virol. 2017. PMID: 28659478 Free PMC article.

5

Identification of a novel HIV-1-neutralizing antibody from a CRF07_BC-infected Chinese donor.

Sun Y, Qiao Y, Zhu Y, Chong H, He Y. Sun Y, et al. Among authors: zhu y. Oncotarget. 2017 Jun 21;8(38):63047-63063. doi: 10.18632/oncotarget.18594. eCollection 2017 Sep 8. Oncotarget. 2017. PMID: 28968970 Free PMC article.

6

Mechanism of HIV-1 Resistance to an Electronically Constrained α-Helical Peptide Membrane Fusion Inhibitor.

Wu X, Liu Z, Ding X, Yu D, Wei H, Qin B, Zhu Y, Chong H, Cui S, He Y. Wu X, et al. Among authors: zhu y. J Virol. 2018 Mar 14;92(7):e02044-17. doi: 10.1128/JVI.02044-17. Print 2018 Apr 1. J Virol. 2018. PMID: 29321334 Free PMC article.

7

Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus.

Zhu Y, Zhang X, Ding X, Chong H, Cui S, He J, Wang X, He Y. Zhu Y, et al. J Biol Chem. 2018 Apr 6;293(14):5323-5334. doi: 10.1074/jbc.RA118.001729. Epub 2018 Feb 7. J Biol Chem. 2018. PMID: 29425101 Free PMC article.

8

Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket.

Zhang X, Zhu Y, Hu H, Zhang S, Wang P, Chong H, He J, Wang X, He Y. Zhang X, et al. Among authors: zhu y. Front Cell Infect Microbiol. 2018 Feb 26;8:51. doi: 10.3389/fcimb.2018.00051. eCollection 2018. Front Cell Infect Microbiol. 2018. PMID: 29535974 Free PMC article.

9

Design of Novel HIV-1/2 Fusion Inhibitors with High Therapeutic Efficacy in Rhesus Monkey Models.

Chong H, Xue J, Zhu Y, Cong Z, Chen T, Guo Y, Wei Q, Zhou Y, Qin C, He Y. Chong H, et al. Among authors: zhu y. J Virol. 2018 Jul 31;92(16):e00775-18. doi: 10.1128/JVI.00775-18. Print 2018 Aug 15. J Virol. 2018. PMID: 29899103 Free PMC article.

10

Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor.

Yu D, Ding X, Liu Z, Wu X, Zhu Y, Wei H, Chong H, Cui S, He Y. Yu D, et al. Among authors: zhu y. J Biol Chem. 2018 Aug 17;293(33):12703-12718. doi: 10.1074/jbc.RA118.003538. Epub 2018 Jun 21. J Biol Chem. 2018. PMID: 29929981 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

55,116 results

Search Page

Filters